Committee staff
Dr Emma Haagensen
Lecturer MBBS
- Email: emma.haagensen@ncl.ac.uk
- Telephone: +44 (0) 191 (20) 84521
- Address: School of Medical Education
Faculty of Medical Sciences
Cookson Building
Newcastle University
NE2 4HH
Publications
- Gardner NJ, Gillespie PJ, Carrington JT, Shanks EJ, McElroy SP, Haagensen EJ, Frearson JA, Woodland A, Blow JJ. The High-Affinity Interaction between ORC and DNA that Is Required for Replication Licensing Is Inhibited by 2-Arylquinolin-4-Amines. Cell Chemical Biology 2017, 24(8), 981-992.e4.
- Gamie Z, Kapriniotis K, Papanikolaou D, Haagensen E, Da Conceicao Ribeiro R, Dalgarno K, Krippner-Heidenreich A, Gerrand C, Tsiridis E, Rankin KS. TNF-related apoptosis-inducing ligand (TRAIL) for bone sarcoma treatment: Pre-clinical and clinical data. Cancer Letters 2017, 409, 66-80.
- Galanos P, Vougas K, Walter D, Polyzos A, Maya-Mendoza A, Haagensen EJ, Kokkalis A, Roumelioti FM, Gagos S, Tzetis M, Canovas B, Igea A, Ahuja AK, Zellweger R, Havaki S, Kanavakis E, Kletsas D, Roninson IB, Garbis SD, Lopes M, Nebreda A, Thanos D, Blow JJ, Townsend P, Sørensen CS, Bartek J, Gorgoulis VG. Chronic p53-independent p21 expression causes genomic instability by deregulating replication licensing. Nature Cell Biology 2016, 18(7), 777-789.
- Beale G, Haagensen E, Thomas H, Wang LZ, Revill C, Payne S, Golding BT, Hardcastle IR, Newell DR, Griffin RJ, Cano C. Combined PI3K and CDK2 inhibition induces cell death and enhances in vivo anti-tumour activity in colorectal cancer. British Journal of Cancer 2016, 115, 682-690.
- Haagensen EJ, Thomas HD, Schmalix WA, Payne AC, Kevorkian L, Allen RA, Bevan P, Maxwell RJ, Newell DR. Enhanced anti-tumour activity of the combination of the novel MEK inhibitor WX-554 and the novel PI3K inhibitor WX-037. Cancer Chemotherapy and Pharmacology 2016, 78(6), 1269-1281.
- Haagensen EJ, Thomas HD, Mudd C, Tsonou E, Wiggins CM, Maxwell RJ, Moore JD, Newell DR. Pre-clinical use of isogenic cell lines and tumours in vitro and in vivo for predictive biomarker discovery; impact of KRAS and PI3KCA mutation status on MEK inhibitor activity is model dependent. European Journal of Cancer 2016, 56, 69-76.
- Moreno A, Carrington JT, Albergante L, AlMamuna M, Haagensen EJ, Komselic ES, Gourgolis VG, Newman TJ, Blow JJ. Unreplicated DNA remaining from unperturbed S phases passes through mitosis for resolution in daughter cells. PNAS 2016, 113(39), E5757-E5764.
- Haagensen EJ, Thomas HD, Wilson I, Harnor SJ, Payne SL, Rennison T, Smith KM, Maxwell RJ, Newell DR. The Enhanced In Vivo Activity of the Combination of a MEK and a PI3K Inhibitor Correlates with [18F]-FLT PET in Human Colorectal Cancer Xenograft Tumour-Bearing Mice. PLoS ONE 2013, 8(12), e81763.
- Haagensen EJ, Kyle S, Beale GS, Maxwell RJ, Newell DR. The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition. British Journal of Cancer 2012, 106(8), 1386-1394.
- Chan CD, Haagensen EJ, Tensaout HA, Rennie KJ, Gamie Z, Barry J, Birch MA, Gerrand CH, Nisar S, Robson CN, Lunec J, Rankin KS. Co‑localisation of intra‑nuclear membrane type‑1 matrix metalloproteinase and hypoxia inducible factor‑2α in osteosarcoma and prostate carcinoma cells. Oncology Letters 2021, 21(2), 158.